Muutke küpsiste eelistusi

E-raamat: Increasing the Therapeutic Ratio of Radiotherapy

Edited by , Edited by
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 159,93 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Current cancer therapies are focused on three general strategies: modifying intrinsic radiosensitivity via molecular targeting, manipulating microenvironmental factors to enhance tumor susceptibility to radiation, and improving delivery of radiation to critical tumor locations while sparing normal tissues. The goal of this volume is to describe a number of promising approaches corresponding to each strategy. In general, research in radiation oncology tends to be siloed into fundamental biology, physics or treatment delivery. The strategies for improving therapeutic ratio encompassed in this book will involve each of these components of radiation oncology. Thus, they will illustrate the variety of disparate approaches available for potentially improving the efficacy of radiotherapy, which may then stimulate discussion across disciplines and foster further translational investigations. Although a goal of each chapter will be to highlight advances within an approach, of equal importance will be the delineation of barriers to successful clinical application and how to overcome or minimize such impediments. Along these lines, because therapeutic ratio incorporates both tumor and normal tissue radio response, a point of emphasis will be the mechanistic rationale for selectively modifying tumor (sensitization) or normal cells (protection). Finally, whereas the literature is replete with studies describing potential targets/strategies for increasing the therapeutic ratio for radiotherapy, this book will focus on those supported by in vivo data consistent with impending translational application along with those that are already being evaluated in the clinic.
Part
1. Molecular Targets.-
1. Improving the therapeutic ratio of radiotherapy by targeting the DNA Damage Response.-
2. Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity.-
3. Histone Deacetylase Inhibitors and Tumor Radiosensitization.-
4. Radioprotection as a Method to Enhance the Therapeutic Ratio of Radiotherapy.- Part
2. Microenvironment.-
5. Application of Functional Molecular Imaging in Radiation Oncology.-
6. Remodeling the Irradiated Tumor Microenvironment: The 5th R of Radiobiology?.-
7. Combining Radiotherapy and Immunotherapy: Emerging Preclinical Observations of Lymphocyte Costimulatory and Inhibitory Receptor Modulation.- Part
3. Clinical.-
8. Stereotactic Body Radiation Therapy (SBRT) or Alternative Fractionation Schedules.-
9. Novel Imaging for Treatment Planning or Tumor Response.-
10. Increasing the Therapeutic Efficacy of Radiotherapy Using Nanoparticles.- Index.
Philip J. Tofilon, Ph.D., is Senior Investigator, Radiation Oncology Branch, National Cancer Institute. Kevin Camphausen, MD, is Branch Chief, Senior Investigator, Radiation Oncology Branch, National Cancer Institute.